drugset / Trial / NCT05196373
Safety, Tolerability, Pharmacokinetics, Immunogenicity and Efficacy of STP705 in Adult Patients With Hypertrophic Scars
Non-randomizedSequentialOpen-labelTreatment
Summary
Adult patients with hypertrophic scars 30 Subjects in Dose Escalation 20 Subjects in Dose Expansion Intrascar injection of STP705 weekly for 4 weeks
Timeline
- Start
- 2023-06
- Primary completion
- 2024-12
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | STP705 | Small interfering RNA (siRNA) | 10 ug | Other |
| Subject | STP705 | Small interfering RNA (siRNA) | 20 ug | Other |
| Subject | STP705 | Small interfering RNA (siRNA) | 40 ug | Other |
| Subject | STP705 | Small interfering RNA (siRNA) | 60 ug | Other |
| Subject | STP705 | Small interfering RNA (siRNA) | 80 ug | Other |
| Subject | STP705 | Small interfering RNA (siRNA) | 100 ug | Other |